Addex Therapeutics Return on Equity (ROE) Growth & History (ADXN)

Addex Therapeutics's return on equity was −93.16% for fiscal 2025.

View full Addex Therapeutics company overview

Addex Therapeutics annual return on equity history

Addex Therapeutics annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-31−93.16%−223.55 pp
20242024-12-31130.39%+478.87 pp
20232023-12-31−348.48%−158.00 pp
20222022-12-31−190.48%−93.13 pp
20212021-12-31−97.35%−33.27 pp
20202020-12-31−64.08%−18.43 pp
20192019-12-31−45.64%−37.54 pp
20182018-12-31−8.11%

Addex Therapeutics return on equity trends

Over the last five fiscal years, Addex Therapeutics's return on equity decreased from −64.08% to −93.16%, a change of −29.08 percentage points. The latest reported quarter, Q1 2026, shows −42.51%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Addex Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about ADXN yet. Start the conversation.

Write the first post